文献速递肿瘤 PET/CT核素与放射性配体治疗

肿瘤临床试验中疗效评估的影像学生物标志物

Imaging for Response Assessment in Cancer Clinical Trials.
PubMed 文献 · Semin Nucl Med · 2020-06-10

本文综述了肿瘤临床试验中用于疗效评估的影像学生物标志物,涵盖CT、MRI和PET的定量指标,包括RECIST、iRECIST、PERCIST等标准,以及DWI、DCE-MRI和FDG/FLT/FMISO-PET等分子影像方法。文章还讨论了AI、抗体/肽类分子影像和诊疗一体化等新兴方向,并指出影像生物标志物在采集和分析的准确性、可重复性方面仍面临挑战。

要点

  • 临床试验常用RECIST、iRECIST和PERCIST等标准化的影像疗效评估指标。
  • DWI的ADC、DCE-MRI的Ktrans和rCBV等MRI指标可反映细胞密度和血管特征。
  • FDG、FLT和FMISO-PET分别反映葡萄糖代谢、增殖和缺氧,用于评估治疗反应。

核心结论

  • 影像生物标志物在肿瘤临床试验的疗效评估中广泛应用,但采集与分析的准确性、重复性和可重复性仍是实施中的主要挑战。

研究设计与样本

  • 本文为综述,围绕CT、MRI和PET影像生物标志物在肿瘤临床试验疗效评估中的应用与挑战进行论述。

主要发现

  • 临床试验中最常用的疗效评估指标来自RECIST,并衍生出用于免疫治疗的iRECIST和用于PET的PERCIST。
  • MRI衍生指标包括DWI的ADC以及DSC或DCE-MRI的Ktrans和rCBV,分别描述细胞密度和血管特征。
  • FDG、FLT和FMISO-PET分别反映葡萄糖代谢、增殖和缺氧,已在多种癌症类型中用于评估靶向和化疗反应。
  • 新兴方向包括AI与机器学习、抗体和肽类分子影像、高级扩散MRI、PSMA和曲妥珠单抗PET、CD8或颗粒酶B PET以及诊疗一体化。

关键数值与推荐

  • 临床试验中最常实施的疗效评估指标来自实体瘤疗效评价标准(RECIST)。
  • 免疫-RECIST(iRECIST)和实体瘤PET疗效评价标准(PERCIST)分别适用于免疫治疗反应和PET成像。
  • MRI指标包括扩散加权MRI的表观扩散系数(ADC)以及DSC或DCE-MRI的Ktrans和相对脑血容量(rCBV)。
  • PET分子标志物包括FDG(葡萄糖代谢)、FLT(增殖)和FMISO(缺氧)。
  • 诊疗一体化示例为68Ga/111In与177Lu-DOTATATE联合使用以指导个体化治疗。

临床怎么用

  • 在肿瘤临床试验中可依据治疗类型选择RECIST、iRECIST或PERCIST等标准化影像指标进行疗效评估。
  • MRI的ADC、Ktrans和rCBV以及PET的FDG、FLT和FMISO可用于反映肿瘤细胞密度、血管特征、代谢、增殖和缺氧状态。
  • 新兴分子影像和AI方法正在进入临床试验,未来有望整合进临床工作流程。

局限性

  • 影像生物标志物的采集和分析在准确性、重复性和可重复性方面仍存在挑战。
  • 新型影像生物标志物的生物学和技术验证仍面临困难。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of biomarkers is integral to the routine management of cancer patients, including diagnosis of disease, clinical staging and response to therapeutic intervention. Advanced imaging metrics with computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) are used to assess response during new drug development and in cancer research for predictive metrics of response. Key components and challenges to identifying an appropriate imaging biomarker are selection of integral vs integrated biomarkers, choosing an appropriate endpoint and modality, and standardization of the imaging biomarkers for cooperative and multicenter trials. Imaging biomarkers lean on the original proposed quantified metrics derived from imaging such as tumor size or longest dimension, with the most commonly implemented metrics in clinical trials coming from the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and then adapted versions such as immune-RECIST (iRECIST) and Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) for immunotherapy response and PET imaging, respectively. There have been many widely adopted biomarkers in clinical trials derived from MRI including metrics that describe cellularity and vascularity from diffusion-weighted (DW)-MRI apparent diffusion coefficient (ADC) and Dynamic Susceptibility Contrast (DSC) or dynamic contrast enhanced (DCE)-MRI (Ktrans, relative cerebral blood volume (rCBV)), respectively. Furthermore, Fluorodexoyglucose (FDG), fluorothymidine (FLT), and fluoromisonidazole (FMISO)-PET imaging, which describe molecular markers of glucose metabolism, proliferation and hypoxia have been implemented into various cancer types to assess therapeutic response to a wide variety of targeted- and chemotherapies. Recently, there have been many functional and molecular novel imaging biomarkers that are being developed that are rapidly being integrated into clinical trials (with anticipation of being implemented into clinical workflow in the future), such as artificial intelligence (AI) and machine learning computational strategies, antibody and peptide specific molecular imaging, and advanced diffusion MRI. These include prostate-specific membrane antigen (PSMA) and trastuzumab-PET, vascular tumor burden extracted from contrast-enhanced CT, diffusion kurtosis imaging, and CD8 or Granzyme B PET imaging. Further excitement surrounds theranostic procedures such as the combination of 68Ga/111In- and 177Lu-DOTATATE to use integral biomarkers to direct care and personalize therapy. However, there are many challenges in the implementation of imaging biomarkers that remains, including understand the accuracy, repeatability and reproducibility of both acquisition and analysis of these imaging biomarkers. Despite the challenges associated with the biological and technical validation of novel imaging biomarkers, a distinct roadmap has been created that is being implemented into many clinical trials to advance the development and implementation to create specific and sensitive novel imaging biomarkers of therapeutic response to continue to transform medical oncology.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sorace AG, Elkassem AA, Galgano SJ, et al. Imaging for Response Assessment in Cancer Clinical Trials. Semin Nucl Med. 2020. PMID: 33059819. doi:10.1053/j.semnuclmed.2020.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。